CL2011000258A1 - Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion. - Google Patents
Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion.Info
- Publication number
- CL2011000258A1 CL2011000258A1 CL2011000258A CL2011000258A CL2011000258A1 CL 2011000258 A1 CL2011000258 A1 CL 2011000258A1 CL 2011000258 A CL2011000258 A CL 2011000258A CL 2011000258 A CL2011000258 A CL 2011000258A CL 2011000258 A1 CL2011000258 A1 CL 2011000258A1
- Authority
- CL
- Chile
- Prior art keywords
- isonicotinamide
- phenylamino
- treatment
- pharmaceutical composition
- inflammation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
Abstract
Compuestos derivados de fenilamino-isonicotinamida; composición a farmacéutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades hiperproliferativas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13785808P | 2008-08-04 | 2008-08-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2011000258A1 true CL2011000258A1 (es) | 2011-07-29 |
Family
ID=41078311
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2011000258A CL2011000258A1 (es) | 2008-08-04 | 2011-02-04 | Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion. |
Country Status (29)
Country | Link |
---|---|
US (2) | US8404725B2 (es) |
EP (1) | EP2307376B1 (es) |
JP (1) | JP2011529963A (es) |
KR (1) | KR101651700B1 (es) |
CN (1) | CN102099336B (es) |
AR (1) | AR072904A1 (es) |
AU (1) | AU2009279940B2 (es) |
BR (1) | BRPI0916566B8 (es) |
CA (1) | CA2732828C (es) |
CL (1) | CL2011000258A1 (es) |
CO (1) | CO6341612A2 (es) |
DK (1) | DK2307376T3 (es) |
EA (1) | EA018539B1 (es) |
EC (1) | ECSP11010867A (es) |
ES (1) | ES2560878T3 (es) |
HK (1) | HK1159097A1 (es) |
HR (1) | HRP20160044T1 (es) |
HU (1) | HUE027223T2 (es) |
IL (1) | IL210937A (es) |
MX (1) | MX2011001127A (es) |
MY (1) | MY151342A (es) |
NZ (1) | NZ591498A (es) |
PE (1) | PE20110665A1 (es) |
PL (1) | PL2307376T3 (es) |
PT (1) | PT2307376E (es) |
SI (1) | SI2307376T1 (es) |
UA (1) | UA107183C2 (es) |
WO (1) | WO2010017051A1 (es) |
ZA (1) | ZA201101661B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013530191A (ja) * | 2010-07-01 | 2013-07-25 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | cis−1,2−ジオールのキログラムスケールでの調製方法 |
WO2012055953A1 (en) * | 2010-10-29 | 2012-05-03 | Bayer Pharma Aktiengesellschaft | Substituted phenoxypyridines |
PT2760821T (pt) | 2011-09-02 | 2018-01-11 | Novartis Ag | Sal de colina de um composto anti-inflamatório de ciclobutenodiona substituída |
CA2920376A1 (en) | 2013-08-07 | 2015-02-12 | Martin Blomberg JENSEN | Methods and composition comprising denosumab or an antibody or antigen binding domain, fragment or derivative thereof, immunoreactive with a rankl/opgbp peptide for use in the treatment, prevention or alleviation of male infertility |
LT3221306T (lt) | 2014-11-20 | 2020-03-10 | Merck Patent Gmbh | Heteroarilo junginiai, kaip irak inhibitoriai ir jų panaudojimas |
US20190008859A1 (en) | 2015-08-21 | 2019-01-10 | Acerta Pharma B.V. | Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor |
CN106632021A (zh) * | 2016-09-27 | 2017-05-10 | 中国药科大学 | 2‑取代异烟酸类化合物、其制备方法及其用途 |
AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
TW202342018A (zh) | 2022-03-04 | 2023-11-01 | 美商奇奈特生物製藥公司 | Mek激酶抑制劑 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5525625A (en) | 1995-01-24 | 1996-06-11 | Warner-Lambert Company | 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
WO1999001426A1 (en) | 1997-07-01 | 1999-01-14 | Warner-Lambert Company | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors |
ES2274572T3 (es) | 1997-07-01 | 2007-05-16 | Warner-Lambert Company Llc | Derivados de acido 2-(4-bromo- o 4-yodo-fenilamino) benzoico y su uso como inhibidor de mek. |
ATE302193T1 (de) | 1999-01-13 | 2005-09-15 | Warner Lambert Co | Benzoheterozyklen und ihre verwendung als mek inhibitoren |
BR9916857A (pt) | 1999-01-13 | 2001-12-04 | Warner Lambert Co | 4 heteroaril diarilaminas |
CA2348236A1 (en) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
CA2349832A1 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Benzenesulfonamide derivatives and their use as mek inhibitors |
AU2482800A (en) | 1999-01-13 | 2000-08-01 | Warner-Lambert Company | Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors |
CZ20012528A3 (cs) | 1999-01-13 | 2002-06-12 | Warner-Lambert Company | 1-Heterocyklicky substituované diarylaminy, farmaceutické kompozice na jejich bázi a způsoby léčení |
GB9910577D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
WO2001068619A1 (en) | 2000-03-15 | 2001-09-20 | Warner-Lambert Company | 5-amide substituted diarylamines as mex inhibitors |
AU2001273498B2 (en) | 2000-07-19 | 2006-08-24 | Warner-Lambert Company | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
UA76837C2 (uk) | 2002-03-13 | 2006-09-15 | Еррей Байофарма Інк. | N3 алкіловані похідні бензімідазолу як інгібітори мек |
SG148857A1 (en) | 2002-03-13 | 2009-01-29 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
GB0215823D0 (en) | 2002-07-09 | 2002-08-14 | Astrazeneca Ab | Quinazoline derivatives |
US20050004186A1 (en) | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
US7956191B2 (en) * | 2004-10-20 | 2011-06-07 | Merck Serono Sa | 3-arylamino pyridine derivatives |
WO2007121269A2 (en) | 2006-04-11 | 2007-10-25 | Ardea Biosciences, Inc. | N-aryl-n'alkyl sulfamides as mek inhibitors |
JP5269762B2 (ja) | 2006-04-18 | 2013-08-21 | アーディア・バイオサイエンシーズ・インコーポレイテッド | Mek阻害剤としてのピリドンスルホンアミドおよびピリドンスルファミド |
CA2671982C (en) | 2006-12-14 | 2016-01-26 | Exelixis, Inc. | Methods of using mek inhibitors |
-
2009
- 2009-07-27 BR BRPI0916566A patent/BRPI0916566B8/pt active IP Right Grant
- 2009-07-27 SI SI200931359T patent/SI2307376T1/sl unknown
- 2009-07-27 WO PCT/US2009/051817 patent/WO2010017051A1/en active Application Filing
- 2009-07-27 PT PT97908420T patent/PT2307376E/pt unknown
- 2009-07-27 KR KR1020117005066A patent/KR101651700B1/ko active IP Right Grant
- 2009-07-27 HU HUE09790842A patent/HUE027223T2/en unknown
- 2009-07-27 JP JP2011522112A patent/JP2011529963A/ja active Pending
- 2009-07-27 AU AU2009279940A patent/AU2009279940B2/en active Active
- 2009-07-27 MX MX2011001127A patent/MX2011001127A/es active IP Right Grant
- 2009-07-27 PE PE2011000115A patent/PE20110665A1/es not_active Application Discontinuation
- 2009-07-27 DK DK09790842.0T patent/DK2307376T3/en active
- 2009-07-27 CA CA2732828A patent/CA2732828C/en active Active
- 2009-07-27 NZ NZ591498A patent/NZ591498A/xx unknown
- 2009-07-27 EA EA201100296A patent/EA018539B1/ru not_active IP Right Cessation
- 2009-07-27 EP EP09790842.0A patent/EP2307376B1/en active Active
- 2009-07-27 UA UAA201102396A patent/UA107183C2/ru unknown
- 2009-07-27 ES ES09790842.0T patent/ES2560878T3/es active Active
- 2009-07-27 PL PL09790842T patent/PL2307376T3/pl unknown
- 2009-07-27 MY MYPI20110408 patent/MY151342A/en unknown
- 2009-07-27 US US13/057,052 patent/US8404725B2/en active Active
- 2009-07-27 CN CN200980128453XA patent/CN102099336B/zh active Active
- 2009-08-04 AR ARP090102980A patent/AR072904A1/es active IP Right Grant
-
2011
- 2011-01-27 IL IL210937A patent/IL210937A/en active IP Right Grant
- 2011-02-02 CO CO11011675A patent/CO6341612A2/es active IP Right Grant
- 2011-02-04 CL CL2011000258A patent/CL2011000258A1/es unknown
- 2011-03-03 EC EC2011010867A patent/ECSP11010867A/es unknown
- 2011-03-03 ZA ZA2011/01661A patent/ZA201101661B/en unknown
- 2011-12-14 HK HK11113513.8A patent/HK1159097A1/xx unknown
-
2013
- 2013-03-05 US US13/785,120 patent/US8889719B2/en active Active
-
2016
- 2016-01-14 HR HRP20160044TT patent/HRP20160044T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2011000258A1 (es) | Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion. | |
CL2012003415A1 (es) | Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer . | |
ECSP12012318A (es) | Inhibidores de pirazolil quinazolina cinasa | |
DOP2014000062A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
CR20150326A (es) | Inhibidores de autotaxina | |
SV2009003307A (es) | Quinazolinas para la inhibicion de pdk1 | |
CL2011003229A1 (es) | Compuestos conjugados derivados de criptoficina; procedimiento de preparacion; y su uso para el tratamiento del cancer. | |
GT200800202A (es) | Quinazolinas para la inhibicion de pdk1 | |
CL2012002189A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos. | |
CL2009000483A1 (es) | Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer. | |
CL2012001821A1 (es) | Compuestos derivados de 5-alquinil-pirimidinas, inhibidores de quinasas; composiciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
CL2008001633A1 (es) | Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer. | |
PA8740901A1 (es) | Compuestos organicos | |
NI201100082A (es) | Compuestos de isoindolina para uso en el tratamiento de cáncer. | |
CL2008003041A1 (es) | Compuestos derivados de acido boronico, inhibidores de proteasoma; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. | |
CL2011000691A1 (es) | Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
CL2008001123A1 (es) | Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer. | |
GT201400090A (es) | 2-tiopirimidinonas | |
CO6721019A2 (es) | Quinazolincarboxamida azetidinas | |
HN2012000023A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
CL2011000165A1 (es) | Compuestos derivados de indolinonas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento y/o la prevencion del cancer, infecciones, enfermedades inflamatorias y autoinmunes. | |
BR112012023836A2 (pt) | composto tricíclicos e inibidores de pbk contendo os mesmos | |
CL2008001728A1 (es) | Compuestos derivados de indolinonas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de cancer, infecciones, enfermedades inflamatorias y autoinmunes. | |
UY33530A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias | |
EA201270728A1 (ru) | Пуриновые соединения |